These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31109711)

  • 1. Cellular therapy for acute myeloid Leukemia - Current status and future prospects.
    Hansrivijit P; Gale RP; Barrett J; Ciurea SO
    Blood Rev; 2019 Sep; 37():100578. PubMed ID: 31109711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
    Pratap S; Zhao ZJ
    Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
    Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
    Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
    Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
    Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
    Mansour AG; Teng KY; Li Z; Zhu Z; Chen H; Tian L; Ali A; Zhang J; Lu T; Ma S; Lin CM; Caligiuri MA; Yu J
    Blood Adv; 2023 Oct; 7(20):6225-6239. PubMed ID: 37379267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
    Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
    Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
    Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Transfer of Umbilical Cord Blood CD34
    Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
    Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
    Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
    Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How close are we to CAR T-cell therapy for AML?
    Gill SI
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
    Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
    Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
    Perriello VM; Rotiroti MC; Pisani I; Galimberti S; Alberti G; Pianigiani G; Ciaurro V; Marra A; Sabino M; Tini V; Spinozzi G; Mezzasoma F; Morena F; Martino S; Salerno D; Ashby JF; Wingham B; Serafini M; Martelli MP; Falini B; Biondi A; Tettamanti S
    Blood Adv; 2023 Jun; 7(12):2855-2871. PubMed ID: 36521101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.